Group 1 - Jiangsu Cable's controlling shareholder plans to increase holdings by 100 million to 150 million yuan [1] - New Tian Green Energy's controlling shareholder and its concerted parties increased their shareholding ratio to 52.43% [1] - Kangyuan Pharmaceutical's six executives plan to buy no less than 120,000 shares [1] Group 2 - Electric Sound's shareholders plan to collectively reduce their holdings by no more than 4% of the company's shares [1] - Xinlong Holdings' shareholder Hainan Zhuhua plans to reduce holdings by no more than 3% [1] - Fuzhijun Technology's controlling shareholder, the Institute of Fujian Academy of Sciences, plans to reduce holdings by no more than 2% [1] Group 3 - Weiteou's controlling shareholder Liao Gaobing and Lileyuan plan to reduce holdings by 2% and 1% respectively [1] - Yingshisheng's controlling shareholder Tang Qiu plans to reduce holdings by no more than 1.86% [1] - Changbai Mountain's shareholder Jilin Sen Gong plans to reduce holdings by no more than 1% [1] Group 4 - Qiming Star's shareholder Tibet Tianchen plans to reduce holdings by no more than 0.07% [1] - Yong'an Pharmaceutical's multiple directors plan to collectively reduce holdings by no more than 235,400 shares [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced that several directors and senior management personnel plan to reduce their shareholdings in the company through centralized bidding transactions within three months after a 15 trading day period following the announcement [1] Summary by Relevant Sections - **Shareholding Details** - A total of 942,000 shares are held by the directors and senior management, accounting for 0.3197% of the total share capital and 0.3258% when excluding shares in the repurchase special account [1] - **Planned Reduction** - The planned reduction involves a maximum of 235,400 shares, which represents 0.0799% of the total share capital and 0.0814% when excluding shares in the repurchase special account [1] - **Control Implications** - The share reduction will not lead to any change in the control of the company [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-64 潜江永安药业股份有限公司 关于公司部分董事、高级管理人员 减持股份的预披露公告 公司部分董事、高级管理人员洪仁贵、方锡权、王志华、熊盛捷、李少波先 生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 潜江永安药业股份有限公司（以下简称"公司"、"本公司"）部分董事、 高级管理人员洪仁贵、方锡权、王志华、熊盛捷、李少波先生，合计持有公司股 份 942,000 股（占公司总股本比例 0.3197%，占剔除公司回购专用账户股份后的 总股本比例 0.3258%）计划自本公告披露之日起十五个交易日后的三个月内以集 中竞价交易方式减持公司股份不超过 235,400 股（占公司总股本比例 0.0799%， 占剔除公司回购专用账户股份后的总股本比例 0.0814%），本次减持不会导致公 司控制权发生变更。 公司于近日收到上述董事、高级管理人员出具的《股份减持计划告知函》， 现将具体情况公告如下： | | | | | 占公司总 | 占剔除公司回购 ...

Company Summary - Yong'an Pharmaceutical (SZ 002365) announced that several directors and senior management, including Hong Rengui, Fang Xiquan, Wang Zhihua, Xiong Shengjie, and Li Shaobo, plan to reduce their holdings by up to approximately 240,000 shares within three months, which represents 0.0799% of the total share capital [1] - The company’s current market capitalization is 5.1 billion yuan [1] Revenue Composition - For the first half of 2025, Yong'an Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 64.14%, health food for 24.67%, chemical manufacturing for 10.88%, and other businesses for 0.32% [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced that several directors and senior management plan to reduce their shareholding in the company through centralized bidding transactions within three months after a 15 trading day period following the announcement [1] Group 1: Shareholding Details - A total of 942,000 shares are held by the directors and senior management, representing 0.3197% of the total share capital and 0.3258% when excluding shares in the company's repurchase special account [1] - The planned reduction will not exceed 235,400 shares, which is 0.0799% of the total share capital and 0.0814% when excluding shares in the company's repurchase special account [1] Group 2: Control Implications - The share reduction will not lead to a change in the company's control [1]

证券日报网讯永安药业11月3日在互动平台回答投资者提问时表示，截至2025年10月20日，公司股东人 数为59707户。 （文章来源：证券日报） ...

Core Viewpoint - Yong'an Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 118.32%, but recent declines in the short term raise questions about future performance [1][2]. Group 1: Stock Performance - On October 31, Yong'an Pharmaceutical's stock rose by 2.01%, reaching 17.23 CNY per share, with a total market capitalization of 5.077 billion CNY [1]. - The stock has experienced a decline of 0.75% over the last five trading days, 1.15% over the last 20 days, and 12.05% over the last 60 days [1]. - The company has appeared on the trading leaderboard 30 times this year, with the most recent appearance on July 21, where it recorded a net buy of -289 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Yong'an Pharmaceutical reported a revenue of 577 million CNY, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 25.496 million CNY, down 58.78% year-on-year [2]. - The company has distributed a total of 401 million CNY in dividends since its A-share listing, with 87.665 million CNY distributed over the last three years [3]. Group 3: Company Overview - Yong'an Pharmaceutical, established on June 18, 2001, and listed on March 5, 2010, is primarily engaged in the research, production, and sales of taurine products, which account for 64.14% of its main business revenue [1]. - The company operates within the pharmaceutical and biological sector, specifically in chemical pharmaceuticals and raw materials, and is involved in various concept sectors including pet economy and e-commerce [2].

Core Viewpoint - The company has disclosed its third-quarter financial report, confirming the accuracy and completeness of the information provided, and has made significant changes in its corporate structure and management [2][12]. Financial Data - The third-quarter financial report has not been audited [11]. - The company reported no need for retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - As of the reporting period, the company holds 5,537,350 shares in its repurchase account, accounting for 1.88% of the total shares, ranking fourth among all shareholders [5]. - The top ten shareholders and their shareholding status have not changed due to any lending or borrowing activities [5]. Corporate Governance Changes - The company has amended its business scope and increased the number of board members from six to seven, adding one employee representative director and one vice chairman [6]. - The supervisory board has been abolished, with its functions transferred to the audit committee of the board [6]. Acquisition and Investment - The company has acquired 49.20% of the shares from minority shareholders of Hubei Ling'an Technology Co., Ltd. for 27 million yuan, resulting in full ownership of the subsidiary [6][7]. Management Changes - The company has elected Chen Zidi as the vice chairman and appointed several new senior management personnel, including Dong Shihao as vice general manager [13]. Legal Matters - The company is involved in a patent infringement lawsuit in the U.S. but received a favorable ruling, with the plaintiff required to compensate for some legal fees [9].

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) reported a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 577 million yuan, representing a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders of the listed company was 25.5 million yuan, down 58.78% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 5.18 million yuan, reflecting a significant decline of 86.17% year-on-year [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 577 million yuan, representing a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders was 25.5 million yuan, down 58.78% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 5.18 million yuan, a decrease of 86.17% year-on-year [1] - Basic earnings per share were reported at 0.0881 yuan [1]